|From: stephen1205 (Rep: 220) reply to stephen1205||Date: 11/20/2012 10:10|
|Forum: Pinks and BB - Msg #78970 - List AMBS msgs ||Thread #673477008 (Rec: 0) |
|explosion in progress....Re: Amarantus BioSciences Wins MANF Patent Challenge in Europe|
Share This Post:
a group effort brings prosperity to all.
| Reply to stephen1205 - Msg #78965 - 11/20/2012 09:51|
Amarantus BioSciences Wins MANF Patent Challenge in Europe
SUNNYVALE, Calif., Nov. 20, 2012 /PRNewswire via COMTEX/ -- Amarantus
BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new
treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury
centered on its proprietary anti-apoptosis therapeutic protein MANF, today
announced the Opposition Division of the European Patent Office upheld Amarantus
Bioscience's European Patent relating to neurotrophic factor MANF, following
opposition by rival Hermo Pharma OY of Finland.
The Opposition Division held that the Opponent's arguments did not prejudice the
maintenance of the Patent as originally granted, with broad claims covering MANF
and its derivatives. The Opponent had not contested the validity of the Patent
on the basis of novelty or inventive step, but had objected to the broad scope
of the claims. However, after due consideration of comprehensive legal and
technical oral submissions from both sides, the Opposition Division rejected the
Opponent's arguments and upheld the claims without restriction.
"This is a highly significant decision for Amarantus, after an extended period
of uncertainty," said Marc Wilkinson PhD, European Patent Attorney of UK firm
Avidity IP, representing Amarantus. "The Opposition Division's decision
validates broad protection for MANF and derivatives across major European
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.